7.05
-0.43 (-5.75%)
| Previous Close | 7.48 |
| Open | 7.48 |
| Volume | 1,303,719 |
| Avg. Volume (3M) | 317,338 |
| Market Cap | 397,866,016 |
| Price / Book | 2.63 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2025 |
| Diluted EPS (TTM) | -1.88 |
| Total Debt/Equity (MRQ) | 1.75% |
| Current Ratio (MRQ) | 17.39 |
| Operating Cash Flow (TTM) | -96.14 M |
| Levered Free Cash Flow (TTM) | -62.11 M |
| Return on Assets (TTM) | -22.56% |
| Return on Equity (TTM) | -32.89% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Astria Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.25 |
|
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.49% |
| % Held by Institutions | 106.43% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 49.00 (Cantor Fitzgerald, 595.04%) | Buy |
| Median | 20.00 (183.69%) | |
| Low | 13.00 (Wedbush, 84.40%) | Hold |
| 13.00 (Jefferies, 84.40%) | Hold | |
| Average | 24.20 (243.26%) | |
| Total | 3 Buy, 2 Hold | |
| Avg. Price @ Call | 9.04 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 15 Oct 2025 | 13.00 (84.40%) | Hold | 11.92 |
| Jefferies | 14 Oct 2025 | 13.00 (84.40%) | Hold | 11.61 |
| Cantor Fitzgerald | 17 Sep 2025 | 49.00 (595.04%) | Buy | 7.39 |
| HC Wainwright & Co. | 17 Sep 2025 | 20.00 (183.69%) | Buy | 7.39 |
| 13 Aug 2025 | 16.00 (126.95%) | Buy | 6.87 | |
| JMP Securities | 13 Aug 2025 | 26.00 (268.79%) | Buy | 6.87 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |